

Agenda Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction

7:00 AM Breakfast and Registrations

8:25 AM Welcome and Introductions

Fredrick Hagemeister, MD

IMMUNO-ONCOLOGY

8:30 AM Checkpoint Inhibition: A Perspective into Future of Novel Therapies for Cancer

Don Gibbons, MD, PhD

IMMUNO-ONCOLOGY MEETS MOLECULAR ONCOLOGY

9:00 AM Immunotherapy Combination with Molecular Therapy

James L. Gulley, MD, PhD

9:30 AM BREAK

IMMUNOTHERAPY CLINICAL STUDIES ACROSS TUMOR TYPES

9:45 AM Malignant Melanoma

Michael Davies, MD

10:10 AM Lung Cancer

John V. Heymach, MD, PhD

10:35 AM Head & Neck Cancers

William A. William, MD

11:00 AM Hematological Malignancies

Fredrick B. Hagemeister, MD

11:25 AM Renal Cell Carcinoma

Eric Jonasch, MD

11:50 AM Bladder Cancer

Arlene O. Siefker-Radtke, MD

12:15 PM Prostate Cancer

Eric Jonasch, MD

12:40 PM LUNCH

1:40 PM Hepatic and Gastrointestinal Cancer

Michael Overman, MD

2:05 PM Ovarian Cancer - Neoantigens

Robert Coleman, MD

CLINICAL TRIAL FORUMS

2:30 PM Immunotherapy Modalities in Combination with Standard of Care

James L. Gulley, MD, PhD

3:00 PM BREAK

3:15 PM Biomarkers for Cancer Immunotherapy

Don Gibbons, MD, PhD

3:45 PM Management of Toxicity Issues with Immunotherapy

John V. Heymach, MD, PhD

4:15 PM Closing Remarks and Adjourn

Fredrick Hagemeister, MD

